ReproCELL Incorporated (4978.T)
JPY 144.0
(-3.36%)
JPY 144.0
(-3.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.1 Billion JPY | -3.2% |
| 2022 | 1.14 Billion JPY | 42.05% |
| 2021 | 803.43 Million JPY | 66.45% |
| 2020 | 482.7 Million JPY | 1.68% |
| 2019 | 474.7 Million JPY | -4.38% |
| 2018 | 496.45 Million JPY | 30.23% |
| 2017 | 381.2 Million JPY | -33.83% |
| 2016 | 576.07 Million JPY | 8.09% |
| 2015 | 532.94 Million JPY | 93.06% |
| 2014 | 276.05 Million JPY | 7.79% |
| 2013 | 256.1 Million JPY | 14.45% |
| 2012 | 223.76 Million JPY | 39.98% |
| 2011 | 159.85 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 327 Million JPY | 10.61% |
| 2023 Q1 | 228.92 Million JPY | -14.26% |
| 2023 FY | 1.1 Billion JPY | -3.2% |
| 2023 Q4 | 295.63 Million JPY | -9.26% |
| 2023 Q3 | 325.81 Million JPY | 20.71% |
| 2023 Q2 | 269.91 Million JPY | 17.9% |
| 2022 Q1 | 261.17 Million JPY | 17.32% |
| 2022 FY | 1.14 Billion JPY | 42.05% |
| 2022 Q4 | 267 Million JPY | 4.81% |
| 2022 Q3 | 254.76 Million JPY | -28.9% |
| 2022 Q2 | 358.3 Million JPY | 37.19% |
| 2021 FY | 803.43 Million JPY | 66.45% |
| 2021 Q4 | 222.6 Million JPY | 16.44% |
| 2021 Q3 | 191.18 Million JPY | -21.98% |
| 2021 Q2 | 245.03 Million JPY | 69.45% |
| 2021 Q1 | 144.61 Million JPY | 43.76% |
| 2020 Q2 | 195.81 Million JPY | 391.15% |
| 2020 FY | 482.7 Million JPY | 1.68% |
| 2020 Q1 | 39.86 Million JPY | -75.9% |
| 2020 Q3 | 146.42 Million JPY | -25.22% |
| 2020 Q4 | 100.59 Million JPY | -31.3% |
| 2019 Q3 | 77.69 Million JPY | -38.2% |
| 2019 FY | 474.7 Million JPY | -4.38% |
| 2019 Q4 | 165.44 Million JPY | 112.93% |
| 2019 Q1 | 105.84 Million JPY | -20.78% |
| 2019 Q2 | 125.72 Million JPY | 18.78% |
| 2018 FY | 496.45 Million JPY | 30.23% |
| 2018 Q4 | 133.61 Million JPY | 10.94% |
| 2018 Q3 | 120.43 Million JPY | -9.99% |
| 2018 Q2 | 133.8 Million JPY | 23.2% |
| 2018 Q1 | 108.6 Million JPY | -2.86% |
| 2017 Q1 | 86.56 Million JPY | -55.98% |
| 2017 Q4 | 111.8 Million JPY | 17.52% |
| 2017 Q3 | 95.13 Million JPY | 8.48% |
| 2017 Q2 | 87.7 Million JPY | 1.31% |
| 2017 FY | 381.2 Million JPY | -33.83% |
| 2016 Q1 | 116.19 Million JPY | -11.01% |
| 2016 FY | 576.07 Million JPY | 8.09% |
| 2016 Q4 | 196.66 Million JPY | 23.29% |
| 2016 Q3 | 159.51 Million JPY | 53.83% |
| 2016 Q2 | 103.69 Million JPY | -10.75% |
| 2015 Q3 | 102.38 Million JPY | -32.87% |
| 2015 Q2 | 152.51 Million JPY | 3.42% |
| 2015 Q1 | 147.47 Million JPY | 28.84% |
| 2015 Q4 | 130.56 Million JPY | 27.52% |
| 2015 FY | 532.94 Million JPY | 93.06% |
| 2014 Q1 | 47.18 Million JPY | -38.44% |
| 2014 Q4 | 114.46 Million JPY | 81.04% |
| 2014 Q3 | 63.22 Million JPY | 23.54% |
| 2014 Q2 | 51.18 Million JPY | 8.47% |
| 2014 FY | 276.05 Million JPY | 7.79% |
| 2013 FY | 256.1 Million JPY | 14.45% |
| 2013 Q3 | 75.41 Million JPY | 32.5% |
| 2013 Q1 | 47.12 Million JPY | 0.0% |
| 2013 Q2 | 56.92 Million JPY | 20.79% |
| 2013 Q4 | 76.64 Million JPY | 1.62% |
| 2012 FY | 223.76 Million JPY | 39.98% |
| 2011 FY | 159.85 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 41.279% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | -1275.641% |
| GNI Group Ltd. | 22.43 Billion JPY | 95.075% |
| Linical Co., Ltd. | 3.77 Billion JPY | 70.761% |
| Trans Genic Inc. | 2.24 Billion JPY | 50.885% |
| MEDINET Co., Ltd. | 98.25 Million JPY | -1024.376% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 55.497% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 14.536% |
| AnGes, Inc. | -3.06 Billion JPY | 136.04% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 721.615% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 88.569% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | -113.558% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | -895.64% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | 23.844% |
| CanBas Co., Ltd. | -984 Million JPY | 212.268% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | -182.034% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 33.296% |
| Chiome Bioscience Inc. | 398.59 Million JPY | -177.154% |
| Kidswell Bio Corporation | 1.03 Billion JPY | -6.286% |
| PeptiDream Inc. | 17.21 Billion JPY | 93.584% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | -3509.613% |
| Ribomic Inc. | -10.5 Million JPY | 10619.158% |
| SanBio Company Limited | -14.5 Million JPY | 7716.671% |
| Healios K.K. | 108 Million JPY | -922.891% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 324065.396% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 1970.951% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 73163.624% |
| StemRIM | -44.34 Million JPY | 2590.974% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 65.315% |
| FunPep Company Limited | -680.28 Million JPY | 262.391% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -1495.266% |
| Stella Pharma Corporation | 217.29 Million JPY | -408.39% |
| TMS Co., Ltd. | -6.95 Million JPY | 15995.281% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | -251.195% |
| Cuorips Inc. | 9.63 Million JPY | -11370.481% |
| K Pharma,Inc. | 910 Million JPY | -21.398% |
| Takara Bio Inc. | 25.45 Billion JPY | 95.66% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | 7.559% |
| StemCell Institute Inc. | 1.57 Billion JPY | 29.898% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 33.721% |
| CellSeed Inc. | 107.15 Million JPY | -930.957% |